97213 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses
#2SICKLED BETA GLOBIN ANTIBODIES
#3RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#4FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFE
#5ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS
#6ANTI-C5 ANTIBODIES COMBINATIONS AND USES THEREOF
#7HLA BINDING VACCINE MOIETIES AND USES THEREOF
#8SEPARATION MEDIA AND PURIFICATION METHODS FOR BLOOD ANTIBODIES USING THE SAME
#9Administration of Anti-HPA-1a Antibodies
#10Method of Administering Anti-HPA-1a Monoclonal Antibody
#11HLA BINDING VACCINE MOIETIES AND USES THEREOF
#12Proteins Comprising Kallikrein Related Paptidase 2 Antigen Binding Domains And Their Uses
#13RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#14Sickled beta globin antibodies
#15Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
#16COMPOSITIONS AND METHODS FOR CORONAVIRUS DETECTION
#17Anti-C5 antibody combinations and uses thereof
#18Antibodies that recognize red blood cell antigens
#19HLA binding vaccine moieties and uses thereof
#20THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS
#21METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP) AND FOR PROVIDING EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
#22Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#23Antibodies against HPA-1a
#24NOVEL AFFINITY CHROMATOGRAPHY MEDIA FOR REMOVAL OF ANTI-A AND/OR ANTI-B ANTIBODIES
#25Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
#26Sickled beta globin antibodies
#27METHOD
#28Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
#29Immunoglobulin compositions and process for obtaining the same
#30Humanized antibodies against Globo H and uses thereof in cancer treatments
#31Compositions and methods for increasing protein half-life in a serum
#32Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#33Antibodies that recognize red blood cell antigens
#34Anti-C5 antibody combinations and uses thereof
#35RNA containing composition for treatment of tumor diseases
#36Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
#37RNA containing composition for treatment of tumor diseases
#38Antibody detection method and system
#39Antibody purification method
#40Methods and tools for Vel blood group typing
#41RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#42COMPOSITION ENRICHED IN ANTI-A AND/OR ANTI-B POLYCLONAL IMMUNOGLOBULINS FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES OR POLYCYTHEMIA
#43Composition Enriched in Anti-A and /or Anti B Polyclonal Immunoglobulins
#44Monoclonal antibodies with enhanced ADCC function
#45METHOD FOR PRODUCING VARIANTS HAVING AN FC WITH IMPROVED SIALYLATION
#46Antibodies that recognize red blood cell antigens
#47Antibodies against HPA-1a
#48NOVEL AFFINITY CHROMATOGRAPHY MEDIA FOR REMOVAL OF ANTI-A AND/OR ANTI-B ANTIBODIES
#49Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#50RNA containing composition for treatment of tumor diseases
#51Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
#52Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)
#53Compositions and methods for increasing protein half-life in a serum
#54Affinity chromatography matrix
#55Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
#56Methods for immune globulin administration
#57Anti-HER3 antibodies binding to the beta-hairpin of HER3
#58Use of ADCC-optimized antibodies for treating low-responder patients
#59Monoclonal antibodies with enhanced ADCC function
#60Methods and tools for vel blood group typing
#61Monoclonal antibodies with enhanced ADCC function
#62Transcription units and the use thereof in expression vectors
#63PREPARATION USEFUL FOR, AND METHOD FOR TREATMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIA (NAIT)
#64Monoclonal antibodies with enhanced ADCC function
#65FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES
#66Use of ADCC-optimized antibodies for treating weak patients
#67Anti-platelet membrane glycoprotein VI monoclonal antibody
#68Anti-Rhesus D Recombinant Polyclonal Antibody and Methods of Manufacture
#69INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS
#70Dual Variable Domain Immunoglobulins and Uses Thereof
#71Monoclonal antibodies with enhanced ADCC function
#72Anti-D monoclonal antibodies
#73Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity
#74METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
#75Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
#76ANTIBODY-MEDIATED REJECTION INHIBITOR
#77POLYPEPTIDES INCLUDING MODIFIED CONSTANT REGIONS
#78Anti-RhD monoclonal antibodies
#79FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES
#80DEGLYCOSYLATED ANTIBODIES
#81Anti-rhesus D monoclonal antibody
#82Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)
#83Monoclonal antibodies with enhanced ADCC function
#84Anti-platelet membrane glycoprotein VI monoclonal antibody
#85TREATMENT OF THROMBOCYTOPENIA
#86Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology
#87Methods for isolation of antibody binding to cells
#88Method for treating infectious disease using monoclonal antibodies
#89Method for treating cancer using monoclonal antibodies
#90Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies
#91Method of treating lewis Y-expressing tumors
#92Cytokine production-inducing antibody
#93METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
#94Use of ADCC-optimized antibodies for treating weak patients
#95POLYPEPTIDES INCLUDING MODIFIED CONSTANT REGIONS
#96Immunoglobulin peptides against heated bovine blood
#97SET OF MEANS FOR TREATING A MALIGNANT PATHOLOGY, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
#98METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
#99INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS
#100PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#101Method for Characterization of a Recombinant Polyclonal Protein
#102METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
#103Compositions and methods for detection of antibody binding to cells
#104Anti-HPA
#105Anti-platelet membrane glycoprotein VI monoclonal antibody
#106TREATMENT OF PATHOLOGIES WHICH ESCAPE THE IMMUNE RESPONSE, USING OPTIMIZED ANTIBODIES
#107Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs
#108ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY
#109METHOD FOR PREPARING ANTIBODIES SELECTIVE FOR ACTIVATING FC RECEPTORS
#110Anti-rhesus D recombinant polyclonal antibody
#111Polyclonal antibody product
#112N-glycosylated antibody
#113PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#114Immunoglobulin peptides against heated bovine blood
#115PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#116Novel lgG3 Antibodies for Stimulating Phagocytosis
#117METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
#118Capture, Concentration And Quantitation Of Abnormal Prion Protein From Biological Fluids Using Depth Filtration
#119Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
#120Polypeptides including modified constant regions
#121Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
#122Anti-rhesus D monoclonal antibodies
#123Use of ADCC-optimized antibodies for treating low-responder patients
#124Compositions and methods for detection of antibody binding to cells
#125Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
#126Nucleic acid molecules correlated with the rhesus weak D phenotype
#127Rh(D)-binding proteins
#128Treatment of pathologies which escape the immune response, using optimised antibodies
#129Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
#130Method of measuring activation of effector cells
#131Monoclonal antibodies with enhanced ADCC function
#132Polypeptides including modified constant regions
#133Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses
#134Ultrastable antibody ionic liquids
#135Ultra-stable protein ionic liquids
#136Ultra-stable protein ionic liquids
#137Ultra-stable protein ionic liquids